ÂÜÀòÂÒÂ×

Mr. McGirr has been a member of our board since October 2013. From March 2013 to June 2014, Mr. McGirr served as a Senior Advisor to the Chief Executive Officer of Cubist Pharmaceuticals, Inc., a publicly traded biopharmaceutical company that was acquired by Merck and Co. in January 2015. He previously served as Senior Vice President and Chief Financial Officer of Cubist from November 2002 to March 2013, and as Treasurer from 2002 until 2003. From 1999 to 2002, Mr. McGirr was the President and Chief Operating Officer of hippo inc., a venture-financed internet technology company, and was also a member the hippo inc. board of directors from 1999 to 2003. From 1996 to 1999, he was the President of GAB Robins North America, Inc., a risk management company, serving also as Chief Executive Officer from 1997 to 1999. Mr. McGirr was a private equity investor from 1995 to 1996. From 1978 to 1995, Mr. McGirr served in various positions within the S.G. Warburg Group, ultimately as Chief Financial Officer, Chief Administrative Officer and Managing Director of S.G. Warburg & Co., Inc., a position held from 1992 to 1995. Mr. McGirr served on the board of directors of Relypsa, Inc. from January 2013 until its acquisition by Galencia AG in September 2016, and Roka Bioscience, Inc. from December 2013 until its acquisition by a subsidiary of the Institute for Environmental Health, Inc. in January 2018. Mr. McGirr serves on the board of Rhythm Pharmaceuticals, Inc. (Nasdq: RYTM), Arsanis Inc. (Nasdaq: ASNS), and Menlo Therapeutics (Nasdaq: MNLO), each a clinical-stage biopharmaceutical company. Mr. McGirr holds a Bachelor of Science degree in civil engineering from the University of Glasgow and a Master of Business Administration degree from The Wharton School at the University of Pennsylvania. Mr. McGirr is chair of the Audit Committee.